Capital Fund Management (CFM)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Capital Fund Management (CFM)’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-2,497	Closed	-$154K	–	2077
2014 Q2	$154K	Buy	+2,497	New	+$145K	﹤0.01%	1610
2014 Q1	–	Sell	-4,550	Closed	-$256K	–	2174
2013 Q4	$256K	Sell	4,550 -1,731	-28%	-$97.3K	﹤0.01%	1505
2013 Q3	$386K	Buy	+6,281	New	+$425K	0.01%	1263

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Fund Management (CFM)'s OREX Position: Q3 2014 in Review

Capital Fund Management (CFM) sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 2,497 shares — an estimated $154K sold.

Capital Fund Management (CFM) first reported a position in OREX in Q3 2013 and held it in 3 quarters. The position peaked at $386K in Q3 2013. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

Capital Fund Management (CFM) reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
Capital Fund Management (CFM) sold 2,497 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $154K.
Capital Fund Management (CFM) first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 3 quarters.
Capital Fund Management (CFM)'s Orexigen Therapeutics, Inc. position peaked at $386K in Q3 2013.
128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2014, filed 31 Oct 2014.